https://www.selleckchem.com/products/vtp50469.html
Unfortunately, the majority of the antibody-based targeted and immune therapeutics have failed to meet their primary efficacy endpoints in early phase trials. However, there are a few promising antibody-based drugs with intriguing preliminary data that merit further investigation, while many more continue to be developed and investigated preclinically, and in early phase trials.The traditional method to measure 13CO2 enrichment in breath involves isotope ratio mass spectrometry (IRMS), which has several limitations such as cost, extens
Like
Comment
Share
